NEW YORK (GenomeWeb) – Immunodiagnostic firm Singulex said today that it closed a $50 million senior secured debt facility with Perceptive Advisors. The firm plans to use the financing to continue to develop its single-molecule counting technology that detects disease-associated biomarkers.
Cantor Fitzgerald acted as exclusive financial advisor and sole placement agent to Singulex.
"The investment will help fuel our continued growth and innovation pipeline, including greater access of our Single Molecule Counting technology via our Sgx Clarity system and point-of-care platform," Singulex CEO and President Guido Baechler said in a statement.
Earlier this month, the Alameda, California-based firm received the CE mark in Europe for its Clarity system and said it planned to pursue the CE mark for its cardiac troponin I assay. In addition, it plans to submit data to the US Food and Drug Administration for clearance in 2018.